Related Experiment Video

Updated: Jul 10, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention

Xinhai Zhang1, Boquan Jin, Chuanshu Huang

  • 1Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA.

Current Cancer Drug Targets
|November 6, 2007
PubMed

Insights

The PI3K/Akt pathway is crucial in cell functions and cancer development. Inhibiting this pathway, potentially with natural compounds, can prevent cancer cell proliferation and promote apoptosis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The Phosphatidylinositol 3-kinase/Protein kinase B (PI3K/Akt) signaling pathway regulates fundamental cellular processes like proliferation and survival.
  • Dysregulation of the PI3K/Akt pathway is increasingly implicated in various stages of cancer development.
  • Hyperactivation of PI3K/Akt can result from upstream signaling (RTKs, GPCRs, carcinogens) or intrinsic pathway alterations (gene amplification, PTEN inactivation).

Purpose of the Study:

  • To highlight the critical role of the PI3K/Akt pathway in cancer.
  • To identify key downstream targets, such as NF-kappaB and AP-1, involved in carcinogenesis.
  • To explore therapeutic strategies targeting the PI3K/Akt pathway for cancer treatment.

Main Methods:

  • Review of existing literature on PI3K/Akt signaling in cancer.
  • Analysis of molecular mechanisms driving PI3K/Akt pathway activation in carcinogenesis.
  • Identification of downstream effectors promoting cancer cell survival and proliferation.

Main Results:

  • The PI3K/Akt pathway's aberrant activation drives cancer cell proliferation and survival.
  • Downstream targets like NF-kappaB and AP-1 are significantly activated in cancer.
  • Inhibition of PI3K/Akt pathway components can impede tumor growth and induce apoptosis.

Conclusions:

  • Targeting the PI3K/Akt pathway offers a promising strategy for cancer therapy.
  • Natural compounds with high affinity and low toxicity for PI3K/Akt are attractive candidates for cancer prevention and treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...